Biogen Begins Phase III Felzartamab Study for Third Kidney Disease

Key Takeaways BIIB has started phase III dosing of felzartamab for primary membranous nephropathy in a global study. The PROMINENT study will compare felzartamab to tacrolimus in 180 moderate-to-high-risk PMN patients. Felzartamab showed antibody reduction and improved kidney markers in earlier phase II PMN studies.Biogen (BIIB) initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult patients with primary membranous nephropathy (PMN). Top-line data ...